Illness-related outcomes of illicit substance use disorder in adolescents with early onset schizophrenia: a multicenter study


TURAN S., Ermiş Ç., ERAY ÇAMLI Ş., Ağaç N., Karakuş O. B., Sağlam Y., ...Daha Fazla

Journal of Addictive Diseases, 2024 (SSCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1080/10550887.2024.2332512
  • Dergi Adı: Journal of Addictive Diseases
  • Derginin Tarandığı İndeksler: Social Sciences Citation Index (SSCI), Scopus, Academic Search Premier, ASSIA, PASCAL, BIOSIS, CINAHL, Criminal Justice Abstracts, Educational research abstracts (ERA), MEDLINE, Social services abstracts, Sociological abstracts, Violence & Abuse Abstracts
  • Anahtar Kelimeler: cannabis, dual diagnosis schizophrenia, Early-onset schizophrenia, stimulants, substance use disorder
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objectives: Lifetime co-occurring substance use disorders are common at the time of presentation for the treatment of primary psychosis. Our aim was to investigate the clinical characteristics of adolescents with early-onset schizophrenia/schizoaffective disorder (EOS), categorized as either with (EOS + SUD) or without SUD (non-SUD/EOS), in a multi-center sample. Methods: Between 2016 and 2022, 255 patients were evaluated across three tertiary-care inpatient units. Diagnoses were confirmed by the treating physician according to the DSM-5 during the hospital stay. The severity of symptoms was measured using the Positive and Negative Syndrome Scale (PANSS). Results: The EOS + SUD group exhibited a higher illness onset, fewer years of education, longer duration of untreated psychosis (DUP), a higher frequency of male gender, more frequent hospitalizations, increased use of clozapine and zuclopenthixol LAI, along with higher rates of post-traumatic stress disorder and conduct disorder. Notably, differences in DUP, clozapine use, and the number of hospitalizations did not persist in the multivariate logistic regression model. Conclusions: Our findings support the notion of SUD playing a role in modifying the course of illness in EOS. Future studies should emphasize exploring treatment responses to medications and interventions among youth with dual diagnoses.